Clinical Trials Browser

Disease × Nivolumab × 90 days × Clear all

NCT06767956 2026-04-13

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Phase 1/2 Withdrawn

Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell